Skip to main content

Novel Biomarkers and Cellular Mechanisms in Breast Cancer: Insights from In Vitro and In Vivo Single-Cell Studies

Edited by:

Shicong Tang, MD, Yunnan Cancer Hospital, China

Submission Status: Open   |   Submission Deadline: 10 June 2025


Cancer Cell International is calling for submissions to our Collection on Novel Biomarkers and Cellular Mechanisms in Breast Cancer: Insights from In Vitro and In Vivo Single-Cell Studies.


Image credit: © VOISIN / PHANIE / Science Photo Library

New Content ItemThis Collection supports and amplifies research related to SDG 3: Good Health & Well-Being.

About the Collection

Breast cancer research has significantly advanced in understanding cellular mechanisms and identifying crucial biomarkers for diagnosis, prognosis, and treatment. Further exploration is necessary to delve into the complexities of breast cancer progression, metastasis, and treatment responses. This collection will showcase pioneering research utilizing single-cell transcriptomics to reveal novel biomarkers and elucidate cellular mechanisms underpinning breast cancer progression and treatment responses. The studies will encompass both in vitro and in vivo research, focusing on metabolic and immunological heterogeneity within the tumour microenvironment. Additionally, it seeks to explore how these insights can be translated into potential therapeutic targets and predictive markers for the efficacy of immunotherapy and chemotherapy, thereby bridging the gap between laboratory findings and clinical strategies.
The collection scope includes, but is not limited to, the following topics:
•     Biomarker identification and validation
•     Tumour heterogeneity in breast cancer
•     Signalling pathways and molecular mechanisms
•     In vitro and in vivo models for breast cancer research
•     Single-cell analysis and its implications
•     Therapeutic targets and personalized medicine.

  1. The immune checkpoint targeting is nowadays an integral part of cancer therapies. However, only a minority of patients experience long-term benefits. Thus, the identification of predictive biomarkers contribut...

    Authors: Verena Schweihofer, Christina Bruss, Stephan Seitz, Gunther Glehr, Madeleine Hetterich, Florian Weber, Maria Hatzipanagiotou, Miriam Fernández-Pacheco Álvarez, Olaf Ortmann, Gero Brockhoff, Richard J. Bauer and Anja Kathrin Wege
    Citation: Cancer Cell International 2025 25:120
    Content type: Research Published on:

  2. Tumor-associated macrophages (TAMs) are pivotal components of the breast cancer (BC) tumor microenvironment (TME), significantly influencing tumor progression and response to therapy. However, the heterogeneit...

    Authors: Qing Wang, Yushuai Yu, Liqiong Ruan, Mingyao Huang, Wei Chen, Xiaomei Sun, Jun Liu and Zirong Jiang
    Citation: Cancer Cell International 2025 25:119
    Content type: Research Published on:

  3. Cancer-associated fibroblasts (CAFs) are highly heterogeneous cells and important components of the breast tumor microenvironment (TME). However, their role and clinical value in ER-positive breast cancer have...

    Authors: Zhi-Hao Yu, Huan-Ling Xu, Shuo Wang, Ying-Xi Li, Gui-Xin Wang, Yao Tian, Zhao-Hui Chen, Wen-Bin Song, Long He, Xin Wang, Xu-Chen Cao and Yue Yu
    Citation: Cancer Cell International 2025 25:82
    Content type: Research Published on:

  4. Ferroptosis is a therapeutic strategy for breast carcinoma (BC). Solasonine (SS) was linked to ferroptosis as a tumor suppressor. However, whether SS could treat BC by activating ferroptosis and its underlying...

    Authors: Wenkai Ge, Min Gao, Yingqi Dai, Gang Zheng, Li Yang, Wenshu Zuo and Xingsong Tian
    Citation: Cancer Cell International 2025 25:49
    Content type: Editorial Published on:

  5. Breast cancer remains the most prevalent malignancy and the leading cause of cancer-related mortality among women worldwide. The primary factors contributing to the deterioration and death of patients with bre...

    Authors: Yidi Jia, Luoming Zhang, Wei Zhou, Shuhua Chen, He Zhang, Liming Liu, Hui Guo, Zhiyong Wang, Yanfen Cui, Ruifang Niu and Fei Zhang
    Citation: Cancer Cell International 2025 25:40
    Content type: Research Published on:

  6. Bromodomain-containing protein (BRD) play a pivotal role in the development and progression of malignant tumours. This study aims to identify prognostic genes linked to BRD-related genes (BRDRGs) in patients w...

    Authors: Wei Chen, Yushuai Yu, Chenxi Wang, Zirong Jiang, Xiewei Huang, Yidan Lin, Hongjing Han, Qing Wang and Hui Zhang
    Citation: Cancer Cell International 2025 25:18
    Content type: Research Published on:

  7. The tertiary lymphoid structure (TLS) is recognized as a potential prognosis factor for breast cancer and is strongly associated with response to immunotherapy. Inducing TLS neogenesis can enhance the immunoge...

    Authors: Xiaokai Fan, Daqin Feng, Donggui Wei, Anqi Li, Fangyi Wei, Shufang Deng, Muling Shen, Congzhi Qin, Yongjia Yu and Lun Liang
    Citation: Cancer Cell International 2025 25:12
    Content type: Research Published on:

  8. Gas therapy represents a promising strategy for cancer treatment, with nitric oxide (NO) therapy showing particular potential in tumor therapy. However, ensuring sufficient production of NO remains a significa...

    Authors: Haiyan Yang, Guangrong Zheng, GuoChen Li, Jincui Chen, Licui Qi, Yong Luo, Tengfei Ke, Jie Xiong and Xiaojuan Ji
    Citation: Cancer Cell International 2024 24:434
    Content type: Research Published on:

  9. The objective of this study was to compare the efficacy and safety of subsequent chemotherapy with single eribulin or utidelone combined with a capecitabine regimen in patients with advanced breast cancer who ...

    Authors: Mengya Feng, Pingping Bi, Yihua Kang, Dechun Yang, Shengnan Ren, Xianping Lu, Guojian Xie, Hai Lei and Dan Mo
    Citation: Cancer Cell International 2024 24:416
    Content type: Research Published on:

  10. This study aimed to compare the performance of amide proton transfer–weighted imaging (APTWI) and diffusion kurtosis imaging (DKI) in differentiating benign from malignant breast lesions, evaluate molecular su...

    Authors: Haiyan Shan, Tengfei Ke, Shasha Bao, Yifan Liu, Na Tan, Xinyan Zhou, Guochen Li, Guangrong Zheng, Yongzhou Xu, Yu Xie, Chengde Liao and Jun Yang
    Citation: Cancer Cell International 2024 24:401
    Content type: Research Published on:

  11. As a common cause of cancer-related deaths in women, BRCA (breast cancer) shows complexity and requires precise biomarkers and treatment methods. This study delves into the molecular makeup of BRCA, focusing o...

    Authors: Yanlin Gu, Zhengyang Feng, Xiaoyan Xu and Liyan Jin
    Citation: Cancer Cell International 2024 24:393
    Content type: Research Published on:

  13. Breast cancer has become the malignant tumor with the first incidence and the second mortality among female cancers. Most female breast cancers belong to luminal-type breast cancer and HER2-positive breast can...

    Authors: Rui-yuan Jiang, Jia-yu Zhu, Huan-ping Zhang, Yuan Yu, Zhi-xin Dong, Huan-huan Zhou and Xiaojia Wang
    Citation: Cancer Cell International 2024 24:356
    Content type: Review Published on:

  14. Breast cancer is currently the most frequent malignant tumor and the leading cause of cancer death among women globally. Although the five-year survival rate for early breast cancer has risen to more than 90%,...

    Authors: Man Chen, Mengya Feng, Hai Lei, Dan Mo, Shengnan Ren and Dechun Yang
    Citation: Cancer Cell International 2024 24:349
    Content type: Review Published on:

  15. Tumor metastasis is a continuous and dynamic process and is a major cause of tumor-related death in triple-negative breast cancer. However, this biological process remains largely unknown in triple-negative br...

    Authors: Guixin Wang, Cangchang Shi, Long He, Yingxi Li, Wenbin Song, Zhaohui Chen, Zhaoyi Liu, Yizeng Wang, Xianghui He, Yue Yu, Yao Tian and Xin Wang
    Citation: Cancer Cell International 2024 24:319
    Content type: Research Published on:

  16. Currently, there are no optimal biomarkers available for distinguishing patients who will respond to immune checkpoint inhibitors (ICIs) therapies. Consequently, the exploration of novel biomarkers that can pr...

    Authors: Yi-Chao Chen, Wei-Zhong Zheng, Chun-Peng Liu, Yong-Qiang Zhao, Jun-Wei Li, Ze-Sen Du, Tian-Tian Zhai, Hao-Yu Lin, Wen-Qi Shi, Shan-Qing Cai, Feng Pan and Si-Qi Qiu
    Citation: Cancer Cell International 2024 24:311
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research and Review articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Novel Biomarkers and Cellular Mechanisms in Breast Cancer: Insights from In Vitro and In Vivo Single-Cell Studies" under the “Details” tab during the submission stage.

Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.